Tumour type and patient survival in pancreatic adenocarcinoma
| Total N | Overall mortality | ||||
| Deaths/person-years | Univariate HR (95% CI) | Stage-matched HR (95% CI) | Multivariate HR (95% CI) | ||
| PDAC | 558 (90%) | 449/1150 | 1 (referent) | 1 (referent) | 1 (referent) |
| Invasive IPMN | |||||
| All | 60 (9.7%) | 31/223 | 0.38 (0.26 to 0.54)† | 0.43 (0.30 to 0.62)† | 0.58 (0.39 to 0.86)** |
| Tubular type | 37 | 20/91 | 0.57 (0.36 to 0.89)* | 0.66 (0.42 to 1.05) | 0.85 (0.53 to 1.36) |
| Colloid type | 16 | 7/85 | 0.22 (0.11 to 0.47)† | 0.25 (0.12 to 0.53)‡ | 0.34 (0.16 to 0.73)** |
| Oncocytic type | 7 | 4/48 | 0.25 (0.091 to 0.67)** | 0.28 (0.10 to 0.76)* | 0.41 (0.15 to 1.15) |
*p<0.05; **p<0.01.
↵† p<0.0001.
↵‡ p<0.0005.
PDAC, pancreatic ductal adenocarcinoma; Invasive IPMN, invasive carcinoma arising in the background of intraductal papillary mucinous neoplasm. Survival analysis excluded six patients who died in the 30-day postoperative period (0.9%) and seven who lost to follow-up.